샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795204

세계의 바이러스 벡터 백신 시장

Viral Vector Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 278 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이러스 벡터 백신 세계 시장은 2030년까지 8억 9,320만 달러에 달할 전망

2024년에 7억 7,340만 달러로 추정되는 바이러스 벡터 백신 세계 시장은 2024-2030년 분석 기간 동안 CAGR 2.4%로 성장하여 2030년에는 8억 9,320만 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 소아 환자는 CAGR 1.8%를 기록하며 분석 기간 종료시에는 5억 2,750만 달러에 달할 것으로 예측됩니다. 성인 환자 부문의 성장률은 분석 기간 동안 CAGR 3.4%로 추정됩니다.

미국 시장은 추정 2억 1,070만 달러, 중국은 CAGR 4.6%로 성장 예측

미국의 바이러스 벡터 백신 시장은 2024년에 2억 1,070만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 1억 6,990만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 4.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 0.9%와 1.8%로 예측됩니다. 유럽에서는 독일이 CAGR 1.3%로 성장할 것으로 예측됩니다.

세계의 바이러스 벡터 백신 시장 - 주요 동향과 촉진요인 정리

바이러스 벡터 백신은 현대 의학에서 예방접종의 전망을 어떻게 재정의했을까?

바이러스 벡터 백신은 면역학에서 가장 혁신적인 혁신 중 하나로 등장하여 강력하고 표적화된 면역반응을 유도하는 강력한 플랫폼을 제공하고 있습니다. 바이러스 벡터 백신은 병원체를 약화시키거나 비활성화시킨 것을 사용하는 기존 백신과 달리, 유전자재조합 바이러스를 사용하여 표적 병원체의 특정 항원을 인간 세포에 전달합니다. 이 전략은 체액성 면역과 세포성 면역을 모두 효율적으로 자극할 수 있어 복잡한 바이러스나 변이가 많은 바이러스에 대항하는 데 매우 중요합니다. 이 기술의 성공은 COVID-19 팬데믹 상황에서 전 세계적으로 인정받게 되었습니다. 옥스포드 아스트라제네카(Oxford AstraZeneca)와 존슨앤드존슨(Johnson & Johnson)이 개발한 백신을 포함한 몇몇 주요 백신은 바이러스 벡터 플랫폼에 의존하고 있었습니다. 이들 백신은 강력한 효능뿐만 아니라 mRNA 백신에 비해 안정성과 유통의 용이성 측면에서 물류 측면에서도 우수하다는 것이 입증되었습니다. COVID-19 외에도 에볼라, 지카, HIV, 결핵, 특정 암 등 다양한 질병의 예방을 목적으로 개발이 진행되고 있습니다. 새롭게 출현하는 병원균에 빠르게 적응하고 여러 항원을 전달할 수 있는 능력은 전염병에 대비하는 데 특히 유용합니다. 또한, 비교적 적은 횟수의 투여로 강력하고 오래 지속되는 면역반응을 유발할 수 있어 자원이 부족한 환경에서 그 매력이 더욱 커지고 있습니다. 전 세계 예방접종 전략이 차세대 플랫폼으로 전환되고 있는 가운데, 바이러스 벡터 백신은 전통적인 접근 방식과 최신 접근 방식을 연결하는 가교 역할을 하며 예방의학의 가능성을 재정의하는 데 중요한 역할을 하고 있습니다.

바이러스 벡터 플랫폼의 역량을 강화하는 과학기술 혁신은 무엇인가?

바이러스 벡터 백신의 개발 분야는 안전성, 유효성, 확장성을 확대하는 과학적, 기술적 진보의 물결에 의해 추진되어 왔습니다. 가장 중요한 기술 혁신 중 하나는 아데노 바이러스, 렌티바이러스, 수포성 구내염 바이러스 등 벡터 유형의 개선이며, 각각 면역원성, 복제 능력, 숙주 범위에 따라 선택되고 조작되고 있습니다. 현대의 유전공학 기술은 이러한 벡터의 정확한 조작을 가능하게 하고, 유전자 페이로드를 효과적으로 전달할 수 있는 능력을 유지하면서 병원성을 제거할 수 있도록 합니다. 또한, 2세대 비복제 바이러스 벡터는 벡터 유발 질환에 대한 우려를 줄여 면역 결핍 환자에게 더 안전한 백신이 될 수 있습니다. 합성생물학의 발전으로 연구자들은 여러 항원 및 면역 조절 단백질을 발현할 수 있는 벡터를 설계할 수 있게 되어 면역 반응의 폭과 지속성을 향상시킬 수 있게 되었습니다. 항원 발현을 최적화하고 숙주와 벡터의 상호작용을 예측하기 위해 하이스루풋 스크리닝 방법과 계산 모델링이 사용되고 있습니다. 제조 기술도 눈에 띄게 향상되어 보다 우수한 세포배양 시스템, 정제 공정, 품질 관리 프로토콜을 통해 보다 신속하고 안정적인 생산이 가능해졌습니다. 보관 및 배송 방법도 더욱 유연해졌고, 표준 냉장 온도에서 안정성을 유지할 수 있는 제품도 등장했습니다. 이러한 과학적 비약적 발전은 바이러스 벡터 백신의 유용성을 높일 뿐만 아니라 감염질환, 종양학, 자가면역질환 등 치료 분야로의 적용을 확대하고 있습니다.

바이러스 벡터 백신이 세계 보건과 신종 질병 대응에 있어 중요한 이유는 무엇일까?

바이러스 벡터 백신은 신종 감염병 위협에 대한 적응성과 개발 속도로 인해 세계 보건 전략의 핵심이 되고 있습니다. 전염병이 발생했을 때 신속하게 대응할 수 있는 능력은 전염병과 팬데믹을 관리하는 데 필수적인 도구가 되고 있습니다. 이러한 능력은 아프리카의 에볼라 백신 배포와 최근 COVID-19 사태에서 두드러지게 나타났습니다. 이러한 백신은 병원체의 유전자 염기서열을 알면 신속하게 설계 및 제조할 수 있기 때문에 특히 긴급 상황의 초기 단계, 즉 촌각을 다투는 경우에 유용합니다. 또한, 강력한 면역원성으로 인해 단 한 번의 접종으로도 효과적인 면역을 생성할 수 있으며, 이는 취약한 집단에서 백신 접종률을 빠르게 달성해야 하는 경우 필수적입니다. 또한, 새로운 백신 플랫폼에 비해 내열성이 높아 접근하기 어려운 지역으로의 전개가 가능합니다. 바이러스 벡터 백신은 감염성 질환 외에도 맞춤형 의료, 특히 종양 특이적 항원을 전달하도록 조정할 수 있는 암 면역요법에서 그 역할이 검토되고 있습니다. 세계보건기구(WHO)와 GAVI를 포함한 세계보건기구는 바이러스 벡터 백신 개발 및 인프라 구축에 많은 투자를 통해 미래의 감염병 발생에 대비하고 있습니다. 바이러스 벡터 기술은 기존의 백신 접근법으로는 대처하기 어려웠던 질병에 대처할 수 있기 때문에 바이러스 벡터 기술은 세계 질병 예방 및 통제의 미래에 필수적인 요소로 자리 잡았습니다.

어떤 시장 역학 및 정책 역학이 바이러스 벡터 백신 분야의 확장에 박차를 가하고 있는가?

바이러스 벡터 백신 시장의 성장은 공중 보건 정책, 제약 기술 혁신, 첨단 예방접종 솔루션에 대한 세계 수요에 기반한 여러 가지 요인이 복합적으로 작용하고 있습니다. 주요 촉진요인 중 하나는 COVID-19 팬데믹 이후 각국 정부와 국제보건기구가 백신 연구와 준비에 대한 우선순위를 높인 것입니다. 바이러스 벡터 백신 개발 파이프라인 확대, 생산능력 향상, 지역적 제조 허브 구축 등에 공공 및 민간 자금이 대거 투입됐습니다. 이를 통해 생명공학 기업 및 위탁 생산업체가 바이러스 벡터 기술에 투자하기 쉬운 환경이 조성되었습니다. 기존 백신의 한계와 복잡한 병원체 및 신종 병원체를 다룰 수 있는 플랫폼의 필요성에 대한 인식이 높아진 것도 시장 성장의 원동력이 되고 있습니다. 또한, 감염성 질환뿐만 아니라 암, 자가면역질환 등 만성질환에도 대응할 수 있는 바이러스 벡터 플랫폼의 유연성이 제품 다각화를 추구하는 제약사들을 매료시키고 있습니다. 규제 당국도 이러한 혁신을 지원하기 위해 적응하고 있으며, 승인 경로를 간소화하고 새로운 타겟에 대한 신속한 개발을 가능하게 하는 플랫폼 기반 접근 방식을 더 많이 수용하고 있습니다. 지적 재산권의 발전, 학계와 산업계의 파트너십, 민관 협력의 확산은 이 분야의 성장 궤도에 더욱 박차를 가하고 있습니다. 또한, 국가 예방접종 일정과 비축품에 바이러스 벡터 백신이 포함되어 있다는 것은 그 안전성과 효과에 대한 조직의 신뢰를 보여주는 증거이기도 합니다. 세계 보건 이슈가 계속 진화하는 가운데, 다양하고 확장 가능하며 효과적인 백신에 대한 수요는 바이러스 벡터 백신 시장의 급속한 확장을 유지할 것으로 예상됩니다.

부문

환자(소아, 성인), 유통 채널(병원, 정부기관)

조사 대상 기업 사례

  • AstraZeneca plc
  • Bharat Biotech
  • CanSino Biologics Inc.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • IDT Biologika
  • Indian Immunologicals Ltd.
  • Johnson & Johnson(Janssen Vaccines)
  • Kangtai Biological Products Co., Ltd.
  • Meissa Vaccines Inc.
  • Merck & Co., Inc.(MSD)
  • Oxford Biomedica
  • ReiThera Srl
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Geno-Immune Medical Institute
  • Shionogi & Co., Ltd.
  • Transgene SA
  • Vaxart, Inc.
  • VaxEquity Ltd.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.28

Global Viral Vector Vaccines Market to Reach US$893.2 Million by 2030

The global market for Viral Vector Vaccines estimated at US$773.4 Million in the year 2024, is expected to reach US$893.2 Million by 2030, growing at a CAGR of 2.4% over the analysis period 2024-2030. Pediatric Patient, one of the segments analyzed in the report, is expected to record a 1.8% CAGR and reach US$527.5 Million by the end of the analysis period. Growth in the Adults Patient segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$210.7 Million While China is Forecast to Grow at 4.6% CAGR

The Viral Vector Vaccines market in the U.S. is estimated at US$210.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$169.9 Million by the year 2030 trailing a CAGR of 4.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

Global Viral Vector Vaccines Market - Key Trends & Drivers Summarized

How Have Viral Vector Vaccines Redefined the Landscape of Immunization in Modern Medicine?

Viral vector vaccines have emerged as one of the most transformative innovations in immunology, offering a powerful platform for inducing strong and targeted immune responses. Unlike traditional vaccines that use weakened or inactivated forms of pathogens, viral vector vaccines employ genetically modified viruses to deliver specific antigens from the target pathogen into human cells. This strategy allows for efficient stimulation of both humoral and cellular immunity, which is critical in combating complex or highly mutable viruses. The success of this technology became globally recognized during the COVID-19 pandemic, where several leading vaccines, including those developed by Oxford-AstraZeneca and Johnson & Johnson, relied on viral vector platforms. These vaccines demonstrated not only strong efficacy but also logistical advantages in terms of stability and ease of distribution compared to some mRNA counterparts. Beyond COVID-19, viral vector vaccines are being developed to prevent a wide range of diseases including Ebola, Zika, HIV, tuberculosis, and certain cancers. Their ability to rapidly adapt to emerging pathogens and deliver multiple antigens makes them particularly valuable in pandemic preparedness. Moreover, their potential to elicit robust and long-lasting immune responses with relatively few doses enhances their appeal in low-resource settings. As global immunization strategies shift toward next-generation platforms, viral vector vaccines are playing a critical role in bridging traditional and modern approaches, redefining what is possible in preventive medicine.

What Scientific and Technological Innovations Are Strengthening the Capabilities of Viral Vector Platforms?

The field of viral vector vaccine development has been propelled forward by a wave of scientific and technological advancements that have expanded its safety, efficacy, and scalability. One of the most important innovations is the refinement of vector types, including adenoviruses, lentiviruses, and vesicular stomatitis viruses, each selected and engineered based on their immunogenic properties, replication competence, and host range. Modern genetic engineering techniques have enabled precise manipulation of these vectors to remove pathogenicity while maintaining their ability to deliver genetic payloads effectively. Furthermore, second-generation and non-replicating viral vectors have reduced concerns over vector-induced disease, making these vaccines safer for immunocompromised individuals. Advances in synthetic biology are allowing researchers to design vectors that can express multiple antigens or immune-modulatory proteins, enhancing the breadth and durability of immune responses. High-throughput screening methods and computational modeling are being used to optimize antigen expression and predict host-vector interactions. Manufacturing technology has also improved significantly, with better cell culture systems, purification processes, and quality control protocols enabling faster and more consistent production. Storage and delivery methods have become more flexible, with some viral vector vaccines capable of remaining stable at standard refrigeration temperatures, a major advantage for distribution in developing regions. Together, these scientific breakthroughs are not only increasing the utility of viral vector vaccines but also expanding their applicability across both infectious diseases and therapeutic areas such as oncology and autoimmune disorders.

Why Are Viral Vector Vaccines Considered Critical in Global Health and Emerging Disease Response?

Viral vector vaccines have become a cornerstone in global health strategies due to their adaptability and speed of development in response to emerging disease threats. Their ability to rapidly deploy in outbreak situations makes them essential tools in managing epidemics and pandemics. This capability was notably demonstrated with the deployment of the Ebola vaccine in Africa and, more recently, during the COVID-19 crisis. These vaccines can be designed and produced quickly once the genetic sequence of a pathogen is known, making them particularly useful in the early stages of a health emergency when time is critical. Furthermore, their strong immunogenicity enables the generation of effective immunity even after a single dose in many cases, which is vital when vaccine coverage must be achieved rapidly in vulnerable populations. Their deployment in hard-to-reach regions is also supported by their greater thermostability compared to some newer vaccine platforms. In addition to infectious diseases, viral vector vaccines are being explored for their role in personalized medicine, especially in cancer immunotherapy where they can be tailored to deliver tumor-specific antigens. Global health organizations, including the World Health Organization and GAVI, are investing heavily in viral vector vaccine development and infrastructure to improve readiness for future outbreaks. The ability to address diseases that have historically been difficult to manage with traditional vaccine approaches makes viral vector technology indispensable to the future of global disease prevention and control.

What Market Forces and Policy Dynamics Are Fueling the Expansion of the Viral Vector Vaccines Sector?

The growth in the viral vector vaccines market is driven by several intertwined factors rooted in public health policy, pharmaceutical innovation, and global demand for advanced immunization solutions. One of the key drivers is the increased prioritization of vaccine research and preparedness by governments and international health bodies in the aftermath of the COVID-19 pandemic. Massive public and private funding has been funneled into expanding viral vector vaccine development pipelines, improving production capacity, and building regional manufacturing hubs. This has created a favorable environment for biotech companies and contract manufacturers to invest in viral vector technologies. Rising awareness of the limitations of traditional vaccines and the need for platforms that can handle complex or emerging pathogens is also contributing to market momentum. In addition, the flexibility of viral vector platforms in addressing not just infectious diseases but also chronic illnesses such as cancer and autoimmune disorders is attracting pharmaceutical companies looking to diversify their product offerings. Regulatory agencies are also adapting to support this innovation, with streamlined approval pathways and greater acceptance of platform-based approaches that allow faster development for new targets. Intellectual property advancements, partnerships between academia and industry, and the growing prevalence of public-private collaborations are further reinforcing the sector’s growth trajectory. Moreover, the inclusion of viral vector vaccines in national immunization schedules and stockpiles signals institutional confidence in their safety and efficacy. As global health challenges continue to evolve, the demand for versatile, scalable, and effective vaccines is expected to sustain the rapid expansion of the viral vector vaccine market.

SCOPE OF STUDY:

The report analyzes the Viral Vector Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Patient (Pediatric Patient, Adults Patient); Distribution Channel (Hospitals Distribution Channel, Government Institutes Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • AstraZeneca plc
  • Bharat Biotech
  • CanSino Biologics Inc.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • IDT Biologika
  • Indian Immunologicals Ltd.
  • Johnson & Johnson (Janssen Vaccines)
  • Kangtai Biological Products Co., Ltd.
  • Meissa Vaccines Inc.
  • Merck & Co., Inc. (MSD)
  • Oxford Biomedica
  • ReiThera Srl
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Geno-Immune Medical Institute
  • Shionogi & Co., Ltd.
  • Transgene SA
  • Vaxart, Inc.
  • VaxEquity Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Viral Vector Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Widespread Immunization Programs Throw the Spotlight on Scalable Viral Vector Platforms
    • Pandemic-Era Acceleration of Vaccine Technologies Continues to Drive Viral Vector Advancements
    • Expanding Pipeline of Infectious Disease Targets Strengthens the Commercial Outlook for Viral Vector Vaccines
    • Adoption of Platform-Based Manufacturing Models Spurs Efficiency in Vaccine Development and Deployment
    • Rising Focus on Durable Immune Response Drives Demand for Adenoviral and Lentiviral Delivery Systems
    • Here's How Advances in Genetic Engineering Are Enhancing the Specificity and Safety of Viral Vectors
    • Global South's Demand for Affordable Vaccine Platforms Expands the Addressable Market for Viral Vectors
    • Concerns Over Pre-Existing Immunity to Common Vectors Spur Innovation in Novel Vector Design
    • Breakthroughs in Cancer Immunotherapy Open New Indications for Viral Vector Vaccine Applications
    • Cold Chain Challenges in Remote Markets Highlight the Need for Thermostable Vector-Based Formulations
    • Rising Consumer and Political Awareness of Vaccine Equity Creates Opportunities for Decentralized Viral Vector Production
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Viral Vector Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Viral Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Viral Vector Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Viral Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pediatric Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pediatric Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pediatric Patient by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adults Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adults Patient by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Adults Patient by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Government Institutes Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Government Institutes Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Government Institutes Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Viral Vector Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Viral Vector Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Viral Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Viral Vector Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Viral Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Viral Vector Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Viral Vector Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Viral Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Viral Vector Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Viral Vector Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Viral Vector Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Viral Vector Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Viral Vector Vaccines by Patient - Pediatric Patient and Adults Patient Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Viral Vector Vaccines by Patient - Percentage Breakdown of Value Sales for Pediatric Patient and Adults Patient for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Viral Vector Vaccines by Distribution Channel - Hospitals Distribution Channel and Government Institutes Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Viral Vector Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Distribution Channel and Government Institutes Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제